NCT04903197 2026-04-01
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
Novartis
National Cancer Institute (NCI)
Teva Branded Pharmaceutical Products R&D, Inc.